Clinical evaluation of temafloxacin in Mycoplasma pneumoniae infections

Keizo Matsumoto, Yoshiaki Utsunomiya, Akira Watanabe, Akira Watanabe, Mitsunobu Honma, Kiyoshi Konno, Hideo Arai, Shigeru Shimoda, Yoshio Uzuka, Harumi Shishido, Hideaki Nagai, Kouji Satoh, Shinobu Akagawa, Kotaro Oizumi, Takafumi Yano, Yoshiyuki Mitsutake, Toshihiro Higashi, Masashi Kawahara, Masazumi Saisho, Hiroshi TakahashiTadao Ise, Shigeo Komatsu, Sumio Arai

Research output: Contribution to journalArticlepeer-review


The clinical effect of temafloxacin (TMFX), a new quinolone antibacterial agent developed by Abbott Laboratories, was investigated in Mycoplasma pneumoniae infections. Clinical specimens, throat swabs and sputum, were collected from 28 adult patients with acute respiratory tract infections, including infections by M. pneumoniae, in 11 hospitals in Japan. The patients were generally treated by oral administration of TMFX 300 mg twice a day for 7~14 days. M. pneumoniae was isolated from 9 patients, and an increase in M. pneumoniae specific antibodies, such as indirect hemagglutinins and complement-fixing antibodies, was observed. An increase in antibodies was observed, in 6 cases, but the attempts at isolation were negative. The clinical evaluation of TMFX in M. pneumoniae infection was conducted in these 15 cases. The clinical response to TMFX was excellent in 6 patients, good in 8 and fair in 1, and the clinical efficacy rate was 93.3%. Bacteriological studies showed that the clinical specimens from which M. pneumoniae was isolated became nagative within 3 ~ 11 days after initiation of TMFX administration. Side effects were observed in 2 cases; dizziness in one, and dizziness and gastrointestinal complaints in the other. Abnormal laboratory findings consisted of one case each of increase in urinary protein and increase in serum potassium. These side effects were transient in both cases. On the basis of these results, it may be concluded that TMFX is a promising antimicrobial agent for the treatment of M. pneumoniae infections.

Original languageEnglish
Pages (from-to)479-488
Number of pages10
Publication statusPublished - 1993
Externally publishedYes


  • M. pneumoniae
  • TA-167
  • temafloxacin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Clinical evaluation of temafloxacin in Mycoplasma pneumoniae infections'. Together they form a unique fingerprint.

Cite this